CompanyGraphAt a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $6.3M, lower than 95% of all stocks globally
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
4.66MGBP6.30M · vs all stocks (USD)
Revenue (TTM)
11.60MGBP15.67M · vs all stocks (USD)
Profit Margin
-7.71%vs Medical Devices peers
Beta
0.0860xvs all stocks
52-Week Change
-28.57%vs all stocks
Market Capitalization
4.66MGBP6.30M · vs all stocks (USD)
Enterprise Value
5.45MGBP7.37M · vs all stocks (USD)
Forward P/E
-0.2250xvs Medical Devices peers
Price to Sales (TTM)
0.3618xvs Medical Devices peers
Price to Book (MRQ)
0.5625xvs Medical Devices peers
Enterprise to Revenue
0.4700xvs Medical Devices peers
Enterprise to EBITDA
-10.87xvs Medical Devices peers
Profit Margin
-7.71%vs Medical Devices peers
Operating Margin
-14.46%vs Medical Devices peers
Return on Assets (TTM)
-3.81%vs Medical Devices peers
Return on Equity (TTM)
-11.06%vs Medical Devices peers
Revenue (TTM)
11.60MGBP15.67M · vs all stocks (USD)
Revenue per Share (TTM)
0.0120GBPUpdated Aug 9, 2026Quarterly Revenue Growth
-5.40%vs Medical Devices peers
Gross Profit (TTM)
3.05MGBP4.12M · vs all stocks (USD)
EBITDA (TTM)
-502.00KGBP-677.97K · vs all stocks (USD)
Net Income (TTM)
-895.00KGBP-1.21M · vs all stocks (USD)
Operating Cash Flow (TTM)
569.00KGBP768.45K · vs all stocks (USD)
Levered Free Cash Flow (TTM)
491.75KGBP664.12K · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Aug 9, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
11.95MGBPFY2024 · Dec 31, 2024Cost of Goods Sold
8.51MGBPFY2024 · Dec 31, 2024Gross Profit
3.44MGBPFY2024 · Dec 31, 2024Operating Income
-638.00KGBP-861.64K · vs all stocks (USD)
Pre-tax Income
-2.05MGBPFY2024 · Dec 31, 2024Income Tax Expense
-107.00KGBPFY2024 · Dec 31, 2024Net Income
-1.94MGBPFY2024 · Dec 31, 2024EBIT
-1.95MGBPFY2024 · Dec 31, 2024EBITDA (Income Statement)
1.21MGBPFY2024 · Dec 31, 2024Research & Development
1.15MGBPFY2024 · Dec 31, 2024Selling, General & Administrative
2.71MGBPFY2024 · Dec 31, 2024Non-operating Interest Expense
99.00KGBPFY2024 · Dec 31, 2024Net Income from Continuing Operations
-1.94MGBPFY2024 · Dec 31, 2024Preferred Stock Dividends
0.00GBPFY2024 · Dec 31, 2024Operating Cash Flow
-2.09MGBPFY2024 · Dec 31, 2024Free Cash Flow
-2.16MGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
195.00KGBPFY2024 · Dec 31, 2024Starting Profit (CF Statement)
-1.94MGBPFY2024 · Dec 31, 2024Stock-based Compensation
0.00GBPFY2024 · Dec 31, 2024Other Non-cash Items
99.00KGBPFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
-133.00KGBPFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
-115.00KGBPFY2024 · Dec 31, 2024Capital Expenditures
-67.00KGBPFY2024 · Dec 31, 2024Net Intangibles (CF)
-268.00KGBPFY2024 · Dec 31, 2024Net Investing Cash Flow
-67.00KGBPFY2024 · Dec 31, 2024Long-term Debt Payments
-353.00KGBPFY2024 · Dec 31, 2024Net Financing Cash Flow
-353.00KGBPFY2024 · Dec 31, 2024Shares Outstanding
932.82MSharesUpdated Aug 9, 2026Float Shares
387.45MSharesUpdated Aug 9, 2026% Held by Insiders
53.97%vs all stocks
% Held by Institutions
20.79%vs all stocks
Total Cash (MRQ)
813.00KGBP1.10M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0010GBPUpdated Aug 9, 2026Total Debt (MRQ)
1.60MGBP2.16M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2097xvs Medical Devices peers
Current Ratio (MRQ)
1.48xvs Medical Devices peers
Book Value per Share (MRQ)
0.0080GBPUpdated Aug 9, 2026Total Assets
12.24MGBP16.53M · vs all stocks (USD)
Total Current Assets
5.32MGBPFY2024 · Dec 31, 2024Total Liabilities
3.70MGBPFY2024 · Dec 31, 2024Total Non-current Assets
6.92MGBPFY2024 · Dec 31, 2024Total Non-current Liabilities
862.00KGBPFY2024 · Dec 31, 2024Total Current Liabilities
2.83MGBPFY2024 · Dec 31, 2024Cash
195.00KGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents
195.00KGBPFY2024 · Dec 31, 2024Accounts Receivable
1.75MGBPFY2024 · Dec 31, 2024Inventory
2.97MGBPFY2024 · Dec 31, 2024Accounts Payable
1.14MGBPFY2024 · Dec 31, 2024Short-term Debt
543.00KGBPFY2024 · Dec 31, 2024Other Current Liabilities
35.00KGBPFY2024 · Dec 31, 2024Long-term Debt
697.00KGBPFY2024 · Dec 31, 2024Common Stock (Book)
9.33MGBPFY2024 · Dec 31, 2024Retained Earnings
-8.95MGBPFY2024 · Dec 31, 2024Total Shareholders' Equity
8.54MGBP11.53M · vs all stocks (USD)
52-Week Low
0.3300GBXUpdated Aug 9, 202652-Week High
0.7380GBXUpdated Aug 9, 202652-Week Change
-28.57%vs all stocks
Beta
0.0860xvs all stocks
50-Day MA
0.4860GBXUpdated Aug 9, 2026200-Day MA
0.4828GBXUpdated Aug 9, 2026Avg 10-Day Volume
72.09KSharesUpdated Aug 9, 2026Avg 30-Day Volume
119.50KSharesUpdated Aug 9, 2026Diluted EPS (TTM)
-0.0010GBPUpdated Aug 9, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Goodwill-Heavy Equity
Equity looks heavy for the industry, but much of it is goodwill from past acquisitions.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $6.3M, lower than 95% of all stocks globallySignificant
Market cap (USD): 6,298,981.461Global P5: 269,387,740.27
Revenue is $15.67M, lower than 95% of all stocks globallySignificant
Revenue (USD): 15,668,849.06Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
XTL Biopharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Purple Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Thalia Therapeutics Plc
Tier 1ProductionApproval-Gated PipelineRule
TheracryF PLC
Tier 1ProductionApproval-Gated PipelineRule
Nuformix Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Sailong Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Crism Therapeutics Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cizzle Biotechnology Holdings Plc
Tier 1ProductionApproval-Gated PipelineRule
Futura Medical plc
Tier 1ProductionApproval-Gated PipelineRule
Genflow Biosciences Plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Bakkt Holdings, Inc.
1 interpretationGoodwill-Heavy Equity
Pulsar Group Plc
1 interpretationGoodwill-Heavy Equity
Anemoi International Ltd.
1 interpretationGoodwill-Heavy Equity